Bharat Biotech gets DCGI's nod to conduct intranasal booster dose trials

Jan 28, 2022

New Delhi [India], January 28 : The Drugs Controller General of India (DCGI) on Friday granted permission to Bharat Biotech to conduct clinical trials...

Bharat Biotech completes clinical development for phase III trials, booster doses for BBV154 intranasal Covid vaccine

Aug 15, 2022

Hyderabad (Telangana) [India], August 15 : Bharat Biotech International on Monday said that BBV154 (intranasal vaccine) has proven to be safe, well-tolerated, and immunogenic...

Bharat Biotech seeks DCGI's approval for its intranasal COVID-19 booster dose clinical trials, submits application

Dec 20, 2021

New Delhi [India], December 20 : As India is witnessing a surge in cases of "highly transmissible" Omicron variant, Hyderabad-based Bharat Biotech has submitted...

DCGI's subject expert committee to hold discussion on 'Five Arms' intranasal heterologous booster dose on Nov 15, sources

Nov 12, 2022

DCGI has already given emergency use authorization (EUA) to BBIL for the intranasal vaccine. BBIL had in September this year applied for DCGI's approval...